Authors (Year) | Country | Setting | Sample size (treatment/control) | Mean age (SD) | Inclusion criteria | Treatment | Primaryoutcome | Findings |
---|---|---|---|---|---|---|---|---|
Gautret et al (2020) | France | Hospitals in Marseille, Nice, Avignon and Briançon | 6 – AZT and HCQ14 – HCQ alone16 – control | Treatment groups: 51.2 (18.7)Control: 37.3 (24.0) |
| Six patients received 500 mg AZT on Day 1 then 250 mg daily for four days and200 mg HCQ three times a day for 10 days.14 patients received 200 mg HCQ three times a day for 10 days. | Outcome of a nasopharyngeal swab on Day 6 | Virological cure:AZT and HCQ – 100%HCQ alone – 57.1%Controls – 12.5% p<0.001 |
AZT = azithromycin; HCQ = hydroxychloroquine.